GHK-Cu vs Thymosin Alpha-1
Two endogenous peptides with very deep clinical histories — but they occupy completely different positions in longevity biology. GHK-Cu is the most-studied connective-tissue and cellular-repair signal; Thymosin Alpha-1 is the only clinical-stage immunosenescence-relevant peptide with a 30-year licensing history outside the UK.
What they are
GHK-Cu is the copper-bound form of the endogenous human tripeptide glycyl-L-histidyl-L-lysine. Plasma levels fall from ~200 ng/mL at age 20 to ~80 ng/mL at age 60. The compound is in long-standing cosmetic use and is the most-studied connective-tissue repair signal in peptide biology.
Thymosin Alpha-1 (Tα1) is a synthetic 28-amino-acid N-acetylated peptide originally derived from thymic tissue. It is licensed in 30+ countries for adjunct treatment of chronic hepatitis B and C and as a vaccine adjuvant in immunocompromised populations.
Mechanism
GHK-Cu acts on three intersecting axes: copper trafficking (delivering Cu²⁺ to enzymes that need it without producing redox-active free copper), genome-wide gene-expression modulation (~4,000 human genes per Pickart et al. 2014), and direct fibroblast/stem-cell signalling driving tissue repair.
Tα1 acts through TLR-2 and TLR-9 on dendritic cells, triggering MyD88-dependent signalling, type-I interferon production, and T-cell maturation. It is broadly immune-restorative rather than immunostimulatory.
Longevity relevance
GHK-Cu's relevance is the breadth of its gene-expression signature — its profile is classified as a 'reverser' of multiple inflammatory and oncogenic transcriptional states, making it a candidate intervention for inflammaging.
Tα1's relevance is its clinical-stage activity on immunosenescence — the age-related decline of adaptive immunity. It is one of the few compounds with documented effects on T-cell maturation and vaccine response in older adults.
Regulatory status
GHK-Cu has cosmetic approval in the UK and EU under standard CPNP notification. Parenteral GHK-Cu is not a licensed medicine. Tα1 holds marketing authorisation in 30+ countries (including Italy, Spain, multiple Latin American and Asian jurisdictions) but does not currently hold UK MHRA authorisation; UK access has historically been via Specials importation.